Merck Welcomes Independent Review of the Safety Profile of JANUVIA® (sitagliptin) and Other Diabetes Medicines

Dateline City:  WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, today issued the following statement regarding this week's NIDDK-NCI Workshop and the American Diabetes Association’s (ADA) call for an independent review of data about the safety of incretin-based diabetes medicines, including GLP-1 analogs and DPP-4 inhibitors such as JANUVIA® (sitagliptin). Language:  English Contact:  MerckMedia:Pam Eisele(267) 664-0282orKim Hamilton(908) 391-0131orInvestor:Carol Ferguson(908) 423-4465 Ticker Slug:  Ticker: MRK Exchange: NYSE read more
Source: - Product News - Category: Drugs & Pharmacology Authors: Tags: Prescription Medicine News Corporate News Latest News Source Type: news